NO930193L - Biarylsubstituerte 4-aminosmoersyreamider - Google Patents

Biarylsubstituerte 4-aminosmoersyreamider

Info

Publication number
NO930193L
NO930193L NO93930193A NO930193A NO930193L NO 930193 L NO930193 L NO 930193L NO 93930193 A NO93930193 A NO 93930193A NO 930193 A NO930193 A NO 930193A NO 930193 L NO930193 L NO 930193L
Authority
NO
Norway
Prior art keywords
low
aryl
low alkyl
alkyl
alkoxy
Prior art date
Application number
NO93930193A
Other languages
English (en)
Norwegian (no)
Other versions
NO930193D0 (no
Inventor
Gary Ksander
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO930193D0 publication Critical patent/NO930193D0/no
Publication of NO930193L publication Critical patent/NO930193L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO93930193A 1992-01-22 1993-01-21 Biarylsubstituerte 4-aminosmoersyreamider NO930193L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/824,132 US5217996A (en) 1992-01-22 1992-01-22 Biaryl substituted 4-amino-butyric acid amides

Publications (2)

Publication Number Publication Date
NO930193D0 NO930193D0 (no) 1993-01-21
NO930193L true NO930193L (no) 1993-07-23

Family

ID=25240671

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93930193A NO930193L (no) 1992-01-22 1993-01-21 Biarylsubstituerte 4-aminosmoersyreamider

Country Status (14)

Country Link
US (2) US5217996A (da)
EP (1) EP0555175A1 (da)
JP (1) JPH05310664A (da)
KR (1) KR930016393A (da)
AU (1) AU666902B2 (da)
CA (1) CA2087652A1 (da)
FI (1) FI930195A7 (da)
HU (1) HUT63376A (da)
IL (1) IL104387A0 (da)
MX (1) MX9300310A (da)
NO (1) NO930193L (da)
NZ (1) NZ245716A (da)
TW (1) TW228513B (da)
ZA (1) ZA93421B (da)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
HRP950558A2 (en) * 1994-11-15 1997-12-31 Scott M. Wilhelm Substituted 4-biarylbutric or biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
EA002348B1 (ru) * 1995-02-22 2002-04-25 Новартис Аг Соединения 1-арил-2-ациламиноэтана и их применение в качестве антагонистов нейрокинина, в частности нейрокинина 1
MY132550A (en) 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
BR0009289A (pt) * 1999-03-29 2002-01-22 Bristol Myers Squibb Co Uso de inibidores da vasopeptidase para tratar angina pectoris
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
EP1467728B1 (en) * 2002-01-17 2007-08-22 Novartis AG Pharmaceutical compositions comprising valsartan and nep inhibitors
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
ATE550656T1 (de) * 2003-08-20 2012-04-15 Alere San Diego Inc Verfahren und zusammensetzungen zur messung biologisch aktiver natriuretischer peptide und zur verbesserung ihres therapeutischen potentials
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) * 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
AU2005275181A1 (en) * 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1781289A1 (en) 2004-07-22 2007-05-09 PTC Therapeutics, Inc. Thienopyridines for treating hepatitis c
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
RU2459809C2 (ru) * 2005-11-09 2012-08-27 Новартис Аг Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP1903027A1 (en) * 2006-09-13 2008-03-26 Novartis AG Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors
BRPI0806700A8 (pt) * 2007-01-12 2019-01-22 Novartis Ag processo
TW200838501A (en) 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TWI406850B (zh) * 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
WO2009035543A1 (en) 2007-09-07 2009-03-19 Theravance, Inc. Dual-acting antihypertensive agents
CN104119336B (zh) * 2007-10-05 2016-08-24 维拉斯通股份有限公司 嘧啶取代的嘌呤衍生物
EP2225210B1 (en) * 2007-12-11 2012-04-25 Theravance, Inc. Dual-acting benzoimidazole derivative and their use as antihypertensive agents
PE20091364A1 (es) 2008-01-17 2009-10-13 Novartis Ag Proceso para la preparacion de inhibidores de nep
AU2012202949B2 (en) * 2008-01-17 2015-01-22 Novartis Ag Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
WO2009134741A1 (en) 2008-04-29 2009-11-05 Theravance, Inc. Dual-acting antihypertensive agents
CN101607875B (zh) * 2008-06-17 2012-07-25 中国石油化学工业开发股份有限公司 制造环烷酮的方法
WO2010011821A2 (en) 2008-07-24 2010-01-28 Theravance, Inc. Dual-acting antihypertensive agents
CN101774941A (zh) * 2009-01-13 2010-07-14 浙江九洲药业股份有限公司 2-酰基氨基-3-联苯基丙酸的制备及拆分方法
WO2010132127A1 (en) 2009-05-13 2010-11-18 Intra-Cellular Therapies, Inc. Organic compounds
CA2763572C (en) * 2009-05-28 2017-10-17 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
MA33364B1 (fr) * 2009-05-28 2012-06-01 Novartis Ag Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
US7956054B2 (en) 2009-07-07 2011-06-07 Theravance, Inc. Dual-acting pyrazole antihypertensive agents
WO2011011232A1 (en) 2009-07-22 2011-01-27 Theravance, Inc. Dual-acting oxazole antihypertensive agents
JO2967B1 (en) * 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
WO2011090929A1 (en) 2010-01-19 2011-07-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
CN102712585B (zh) * 2010-01-22 2015-06-24 诺华股份有限公司 中性内肽酶抑制剂中间体和其制备方法
CA2806780A1 (en) * 2010-08-23 2012-03-01 Novartis Ag Process for the preparation of intermediates for the manufacture of nep inhibitors
ES2608780T3 (es) * 2010-08-23 2017-04-17 Novartis Ag Nuevo proceso para la preparación de intermediarios útiles para la elaboración de inhibidores de NEP
ES2702529T3 (es) 2010-08-24 2019-03-01 Novartis Ag Una composición farmacéutica para uso en la prevención o tratamiento de la insuficiencia cardíaca en un mamífero que recibe terapia anticoagulante
US8673974B2 (en) * 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8993631B2 (en) * 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
JP5944922B2 (ja) 2010-12-15 2016-07-05 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
BR112013016595B1 (pt) * 2010-12-15 2021-04-27 Theravance Biopharma R&D Ip, Llc Composto inibidor de neprilisina, processos para a preparação e intermediários do referido composto, composição farmacêutica e uso do composto
JP5959066B2 (ja) 2011-02-17 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
MX342212B (es) 2011-02-17 2016-09-20 Theravance Inc Inhibidores de neprilisina.
JP5885832B2 (ja) 2011-05-31 2016-03-16 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
JP5959075B2 (ja) 2011-05-31 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
US8513244B2 (en) 2011-05-31 2013-08-20 Theravance, Inc. Neprilysin inhibitors
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
AR089955A1 (es) * 2012-02-15 2014-10-01 Theravance Inc Proceso para preparar compuestos de acido 4-amino-5-bifenil-4-il-2-hidroximetil-2-metil-pentanoico
JP6088047B2 (ja) 2012-05-31 2017-03-01 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 一酸化窒素ドナーであるネプリライシン阻害剤
PL2864292T3 (pl) 2012-06-08 2017-10-31 Theravance Biopharma R&D Ip Llc Inhibitory neprylizyny
CA2873328A1 (en) 2012-06-08 2013-12-12 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
MX366149B (es) 2012-08-08 2019-06-28 Theravance Biopharma R&D Ip Llc Inhibidores de neprilisina.
SI2887961T1 (sl) * 2012-08-24 2021-08-31 Novartis Ag Zaviralci NEP za zdravljenje bolezni, značilnih po atrialni širitvi ali preoblikovanju
AU2014216417B2 (en) 2013-02-14 2016-05-12 Novartis Ag Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
WO2014126979A1 (en) 2013-02-14 2014-08-21 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
JP6549040B2 (ja) 2013-02-17 2019-07-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
PT2964616T (pt) 2013-03-05 2017-08-08 Theravance Biopharma R&D Ip Llc Inibidores da neprilisina
CN104230865B (zh) * 2013-06-13 2018-01-09 上海翰森生物医药科技有限公司 联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
SI4321157T1 (sl) 2013-08-26 2025-03-31 Novartis Ag Nova uporaba kombinacije blokatorja receptorja angiotenzina (arb) z nevtralnim zaviralcem endopeptidaze (nepi)
JP2016530282A (ja) 2013-08-26 2016-09-29 ノバルティス アーゲー 新規使用
CA2934936A1 (en) 2014-01-30 2015-08-06 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
RU2016135057A (ru) 2014-01-30 2018-03-12 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Производные 5-бифенил-4-гетероарилкарбониламинопентановой кислоты в качестве ингибиторов неприлизина
WO2015154673A1 (en) * 2014-04-10 2015-10-15 Zhaoyin Wang Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases
WO2016022893A1 (en) 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
CN105622452A (zh) * 2014-08-27 2016-06-01 上海翰森生物医药科技有限公司 Ahu-377结晶型游离酸及其制备方法和应用
CN105367438A (zh) * 2014-08-27 2016-03-02 上海翰森生物医药科技有限公司 AHU-377α-苯乙胺盐多晶型及其制备方法和应用
WO2016029828A1 (zh) * 2014-08-27 2016-03-03 上海翰森生物医药科技有限公司 AHU-377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用
CN105461587A (zh) * 2014-08-27 2016-04-06 上海翰森生物医药科技有限公司 Ahu-377半钙盐晶型及其制备方法和应用
WO2016037098A1 (en) 2014-09-04 2016-03-10 Concert Pharmaceuticals, Inc. Deuterated sacubitril
PL3218351T3 (pl) 2014-11-14 2019-12-31 Zentiva K.S. Sposób wytwarzania, wyodrębniania i oczyszczania farmaceutycznie dopuszczalnych postaci AHU-377
CN105693543B (zh) * 2014-12-15 2018-08-10 四川海思科制药有限公司 沙库比曲类衍生物、其药物组合物、制备方法及用途
CN104557600B (zh) * 2015-01-26 2016-05-04 苏州明锐医药科技有限公司 沙库比曲的制备方法
US9433598B2 (en) 2015-02-11 2016-09-06 Theravance Biopharma R&D Ip, Llc (2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid
TW201632493A (zh) 2015-02-13 2016-09-16 諾華公司 新穎方法
RS61325B1 (sr) 2015-02-19 2021-02-26 Theravance Biopharma R&D Ip Llc (2r,4r)-5-(5'-hloro-2'-fluorobifenil-4-il)-2-hidroksi-4-[(5-metiloksazol-2-karbonil)amino]pentanska kiselina
WO2016135751A1 (en) 2015-02-25 2016-09-01 Mylan Laboratories Limited Novel process for the preparation of sacubitril and its intermediates
CN110801452B (zh) * 2015-03-12 2023-01-13 深圳信立泰药业股份有限公司 一种含有阿利沙坦酯水解产物或其水解产物盐的药物组合物及其用途
MX2017012110A (es) * 2015-03-20 2018-02-19 Crystal Pharmatech Co Ltd Forma cristalina de ahu377, metodo de preparacion y uso de la misma.
RS64242B1 (sr) 2015-05-11 2023-06-30 Novartis Ag Režim doziranja sakubitril-valsartana za lečenje srčane insuficijencije
EP3302460A1 (en) 2015-05-29 2018-04-11 Novartis AG Sacubitril and valsartan for treating metabolic disease
CN104860894B (zh) * 2015-06-10 2017-05-17 北京博全健医药科技有限公司 一种抗心衰药lcz696的制备方法
WO2016201238A1 (en) 2015-06-12 2016-12-15 Teva Pharmaceuticals International Gmbh Solid state forms of trisodium valsartan: sacubitril
WO2016203500A2 (en) 2015-06-19 2016-12-22 Actavis Group Ptc Ehf. Preparation of sacubitril or salt thereof and novel intermediates in the preparation of sacubitril
EP3317248B1 (en) 2015-07-02 2020-09-16 Novartis AG Sacubitril calcium salts
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
WO2017009784A1 (en) 2015-07-14 2017-01-19 Cadila Healthcare Limited Solid state forms of trisodium salt of valsartan/sacubitril complex and sacubitril
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2017013010A1 (de) 2015-07-23 2017-01-26 Bayer Pharma Aktiengesellschaft Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung
WO2017029261A1 (de) * 2015-08-19 2017-02-23 Bayer Pharma Aktiengesellschaft Kombinationspräparat umfassend finerenone und einen nep-inhibitor (sacubitril)
WO2017033128A1 (en) 2015-08-25 2017-03-02 Novartis Ag Biphenyl-substitued 4-amino-butyric acid derivatives and their use in the synthesis of nep inhibitors
US10596151B2 (en) 2015-08-28 2020-03-24 Novartis Ag Methods and pharmaceutical compositions for reducing arterial stiffness with a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme
WO2017051326A1 (en) 2015-09-23 2017-03-30 Novartis Ag New processes and intermediates useful in synthesis of nep inhibitors
WO2017072636A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical synergistic combination
US10377697B2 (en) 2015-12-10 2019-08-13 Novartis Ag Process and intermediates
WO2017097275A1 (en) * 2015-12-11 2017-06-15 Zentiva, K.S. Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method
CN106977417A (zh) * 2016-01-15 2017-07-25 常州方楠医药技术有限公司 一种沙库比曲钠盐的晶型及其制备方法
EP4609912A3 (en) 2016-02-03 2025-11-12 Novartis AG New use of a combination of sacubitril and valsartan
RS62172B1 (sr) 2016-03-08 2021-08-31 Theravance Biopharma R&D Ip Llc Kristalna (2s,4r)-5-(5’-hloro-2-fluoro-[1,1’-bifenil]-4-il)-2-(etoksimetil)-4-(3-hidroksi izoksazol-5-karboksamido)-2-metilpentanska kiselina i njene upotrebe
WO2017172795A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
CN105753733B (zh) * 2016-04-15 2019-06-18 苏州晶云药物科技股份有限公司 Ahu377的晶型及其制备方法与用途
CN105820064A (zh) * 2016-04-18 2016-08-03 浙江天宇药业股份有限公司 一种联苯基丙氨醇衍生物的合成方法及中间体
WO2017191620A1 (en) * 2016-05-06 2017-11-09 Sun Pharmaceutical Industries Limited A crystalline form of a salt of sacubitril and a process of its preparation
WO2018007919A1 (en) 2016-07-05 2018-01-11 Novartis Ag New process for early sacubitril intermediates
CN107602399B (zh) * 2016-07-11 2020-09-25 江西东邦药业有限公司 一种脑啡肽酶抑制剂中间体的制备方法
EP3500549B1 (en) * 2016-08-17 2020-12-16 Novartis AG New processes and intermediates for nep inhibitor synthesis
CN106318988B (zh) * 2016-08-23 2020-11-03 迪嘉药业集团有限公司 一种lcz696关键中间体的制备方法
CN109661386A (zh) * 2016-09-07 2019-04-19 诺瑞特国际药业股份有限公司 沙库比曲钠盐新晶型
CN106478437A (zh) * 2016-09-27 2017-03-08 南通常佑药业科技有限公司 一种γ‑氨基戊酸酯衍生物的制备方法
CN106496055A (zh) * 2016-10-09 2017-03-15 杭州科巢生物科技有限公司 一种抗心衰新药的关键组分沙库比曲的新合成方法
US10857132B2 (en) 2016-10-10 2020-12-08 Laurus Labs Limited Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof
KR20190077467A (ko) 2016-10-28 2019-07-03 바이오콘 리미티드 비정질 삼나트륨 사쿠비트릴 발사르탄 및 이의 제조방법
CN110088079A (zh) 2016-12-23 2019-08-02 诺华股份有限公司 用于早期沙卡布曲中间体的新方法
WO2018153895A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten
CN106831473B (zh) * 2017-02-22 2019-07-16 江西瑞雅药业有限公司 3-酰胺基-4-(2’-烷氧基-4-联苯基)丁酸衍生物及其制备方法、药物组合物
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
MX391562B (es) 2017-07-28 2025-03-21 Synthon Bv Composicion farmaceutica que comprende sacubitril y valsartan
US20200276129A1 (en) 2017-10-13 2020-09-03 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Tablet containing valsartan and sacubitril
CN108530371B (zh) * 2017-12-27 2020-09-01 浙江天宇药业股份有限公司 一种沙库比曲钠盐、沙库比曲游离酸与乙酸的共晶物、其晶型、晶型的制备方法及用途
US11839614B2 (en) 2018-01-31 2023-12-12 Intra-Cellular Therapies, Inc. Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
UY38072A (es) * 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
GB201810326D0 (en) * 2018-06-22 2018-08-08 Johnson Matthey Plc Crystalline form of sacubitril, its preparation and use
KR20210032437A (ko) 2018-08-23 2021-03-24 노파르티스 아게 심부전의 치료를 위한 신규한 약제학적 용도
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
CN109503404A (zh) * 2018-12-28 2019-03-22 凯瑞斯德生化(苏州)有限公司 一种lcz-696关键中间体的制备方法
CN110128298B (zh) * 2019-06-13 2021-08-03 南京一心和医药科技有限公司 一种沙库巴曲中间体的合成方法
CN113135836A (zh) * 2020-01-20 2021-07-20 鲁南制药集团股份有限公司 一种沙库巴曲钙盐的制备方法
CN111253425B (zh) * 2020-02-21 2022-04-29 常州南京大学高新技术研究院 一种1,3-双[2-(3,4-环氧环己基)乙基]四甲基二硅氧烷的合成方法
JP7064527B2 (ja) * 2020-05-01 2022-05-10 ノバルティス アーゲー サクビトリルカルシウム塩
KR20220012821A (ko) 2020-07-23 2022-02-04 주식회사 종근당 이중 작용 복합 화합물의 결정형 및 이의 제조방법
CN112661671B (zh) * 2020-12-22 2022-04-22 江苏阿尔法药业股份有限公司 一种沙库巴曲中间体的制备方法
WO2022224274A1 (en) 2021-04-20 2022-10-27 Mylan Laboratories Limited Polymorphic forms of sacubitril-telmisartan (1:1)
CN117645555A (zh) * 2023-11-30 2024-03-05 南京欧信医药技术有限公司 一种利用连续流管式反应器合成沙库巴曲中间体的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE250531C (da) *
US2543267A (en) * 1950-01-04 1951-02-27 Parke Davis & Co Hydroxyethyl-acylamidobiphenylyl ketones
US4206232A (en) * 1976-05-10 1980-06-03 E. R. Squibb & Sons, Inc. Relieving hypertension with carboxyalkylacylamino acids
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4721726A (en) * 1980-12-18 1988-01-26 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
US4939261A (en) * 1984-06-08 1990-07-03 Ciba-Geigy Corporation N-substituted butyramide derivatives useful for treatment of conditions responsive to inhibition of enkephalinase
US5096925A (en) * 1984-06-08 1992-03-17 Ciba-Geigy Corporation N-substituted butyramide derivatives
EP0225292A3 (en) * 1985-12-06 1988-11-30 Ciba-Geigy Ag Certain n-substituted butyramide derivatives
DD250531A1 (de) * 1985-12-23 1987-10-14 Adw Ddr Verfahren zur herstellung von malonylaminosaeure-p-nitrobenzylestern
CA1337400C (en) * 1987-06-08 1995-10-24 Norma G. Delaney Inhibitors of neutral endopeptidase
WO1989004821A1 (en) * 1987-11-25 1989-06-01 Pfizer Inc. N-(biphenylmethyl)-3-hydroxyglutaramic acid and derivatives as hypocholesterolemic agents
WO1991005555A2 (en) * 1989-10-13 1991-05-02 The Salk Institute Biotechnology/Industrial Associates, Inc. N-acyl peptide metalloendopeptidase inhibitors and methods of using same
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides

Also Published As

Publication number Publication date
IL104387A0 (en) 1993-05-13
NZ245716A (en) 1995-07-26
JPH05310664A (ja) 1993-11-22
ZA93421B (en) 1993-07-22
FI930195A0 (fi) 1993-01-18
CA2087652A1 (en) 1993-07-23
US5217996A (en) 1993-06-08
HU9300166D0 (en) 1993-04-28
MX9300310A (es) 1993-07-01
US5354892A (en) 1994-10-11
HUT63376A (en) 1993-08-30
AU666902B2 (en) 1996-02-29
FI930195A7 (fi) 1993-07-23
NO930193D0 (no) 1993-01-21
KR930016393A (ko) 1993-08-26
TW228513B (da) 1994-08-21
AU3184293A (en) 1993-07-29
EP0555175A1 (en) 1993-08-11

Similar Documents

Publication Publication Date Title
NO930193L (no) Biarylsubstituerte 4-aminosmoersyreamider
HUP0003921A2 (hu) VLA-4 által közvetített leukocitaadhéziót gátló szulfonilezett dipeptidszármazékok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
AU551239B2 (en) Substituted acyl derivatives of 1,2,3,4-tetrahydro isoquinoline-3-carboxylic acids
DK323688A (da) Pyridinforbindelser
NO921719L (no) Fosfono/biaryl-substituerte dipeptidderivater
IL79729A (en) Dibenzoxepine derivatives,their preparation and pharmaceutical compositions containing them
IE810463L (en) Octahydroindole carboxylic acids
DE69728544D1 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
FI895046A0 (fi) 4-amino-3-acylkinolinderivat samt deras anvaendning saosom inhibitorer av sekretion av matsmaeltningsvaetskor.
NO942568D0 (no) 1-aryloksy-3-alkylamino-2-propanolitratestere, deres anvendelse og tilsvarende farmasöytiske blanding
IE832680L (en) Nitrosourea derivatives.
ES8100275A1 (es) Un procedimiento para la preparacion de derivados de 5-fluoruracilo
DK347387D0 (da) Amidderivater
EP0201349A3 (en) Tetrazole derivatives
ATE18993T1 (de) Dibenzocycloheptenyliden-verbindungen zur verwendung bei der modulation der immunreaktion.
IE902273L (en) Compositions of 5-phenyl-2-furan esters amides and ketones
ATE222583T1 (de) Derivate substituierter amidinonaphthylester
AU6924094A (en) PsoralenTM* derivatives, their preparation and use
DK210387D0 (da) Heterocykliske forbindelser og fremgangsmaade til deres fremstilling samt farmaceutiske midler indeholdende disse
GB1309714A (en) Propionic acid derivatives and therapeutic compositions containing them